ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

Olmutinib

HCID 54758501
反応を作成
印刷
基本情報概要名称と識別子物性化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
1353550-13-6
標準SMILES
C=CC(=O)Nc1cccc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3ccsc23)c1
InChIKey
FDMQDKQUTRLUBU-UHFFFAOYSA-N
分子式
C26H26N6O2S
平均分子量
486.6 g/mol
単同位体質量
486.18379527

概要

Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016.

名称と識別子

優先名称
Olmutinib
IUPAC
N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
英語名
HM-61713 (BI-1482694)
分子量
0

名称と別名

Olmutinib1353550-13-6BI 1482694HM-61713N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamideBI-1482694CHL9B67L952-Propenamide, N-[3-[[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-DTXSID0013191192-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)-N-{3-[(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamideN-(3-((2-(4-(4-Methylpiperazin-1-yl)anilino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide
名称をさらに表示
HM-61713 (BI-1482694)NSC 163501ANTIBIOTIC AT-125U 42126HM 61713BI1482694
N-[3-({2-[4-(4-Methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl}oxy)phenyl]prop-2-enamideolmutinibumN-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamideN-(3-(2-(4-(4-methylpiperazin-1-yl)anilino)thieno(3,2-d)pyrimidin-4-yl)oxyphenyl)prop-2-enamideRefChem:856756L01XE40DTXCID401748550HM61713

物性

構造計算による物性

XLogP
4.7
極性表面積
111 Ų
水素結合供与体数
2
水素結合受容体数
8
回転可能結合数
7
重原子数
35
形式電荷
0
複雑度
712

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15

化学と産業

薬理情報

ATC Code · 2 件

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingData not yet available.
Pharmacodynamics · 1 件

Olmutinib selectively and irreversibly binds and inhibits epidermal growth factor receptors (EGFR) with the T790M activating mutation. EGFRs are frequently over-expressed in lung cancer and contribute to activation of the phosphoinositide 3-kinase and mitogen activated protein kinase pathways which both promote cell survival and proliferation. By inhibiting EGFR activation, olmutinib attenuates the activation of these tumor promoting pathways.

Mechanism of Action · 1 件

Olmutinib covalently binds a cysteine residue near the kinase domain of mutant EGFRs to prevent phosphorylation of the receptor. This inhibits receptor signalling as phosphorylation is necessary for recruitment of signalling cascade proteins.

Biological Half-Life8-11h.
Metabolism/MetabolitesData not yet available.
Absorption, Distribution and Excretion · 4 件

tmax of 3-4h with oral administration.

Data not yet available.

Data not yet available.

Data not yet available.

関連反応

3 件
反応記録を作成
HRID 526057 の反応式
HRID 526057生成物として
HRID 1850015 の反応式
HRID 1850015反応物として
HRID 1850016 の反応式
HRID 1850016生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性化学と産業関連反応化合物ノート

データベース識別子

CAS
1353550-13-6、1802181-20-9
PubChem CID
54758501
DTXSID
DTXSID001319119
ChEMBL
CHEMBL3786343
UNII
CHL9B67L95
Nikkaji
J3.435.413H